Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Orofacial cleft 1 candidate 1 (abbreviated OFCC1) is a pseudogene located on human chromosome 6 and associated genomically with risk for orofacial cleft disorders[1][2][6][8]. Although originally identified as a potential causal locus and described with a variety of alternative names (MRDS1, Opo, Ojoplano), current evidence does not support its function as a classic protein target, receptor, enzyme, or part of a signaling pathway. There is no robust data confirming it encodes a functional protein or contributes directly to cellular or molecular biology. OFCC1 has been described in genome-wide association studies for cleft disorders and is sometimes cited in connection with rare genetic variants and non-cleft phenotypes (e.g., Tourette syndrome), but the absence of molecular function or experimental evidence validates it only as a genomic locus without druggable properties or direct clinical relevance as a molecular target[1][5][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Orofacial cleft 1 candidate 1 (pseudogene) (OFCC1).